News ArticleAnupam Rasayan India Ltd Posts 21% Revenue Rise and 38% EBITDA Growth in H1 FY27
Company signs six-year supply deal with US specialty metal manufacturer and acquires controlling 50.07% stake in Bliss GVS Pharma
Anupam Rasayan India Limited announced its consolidated financial results for the quarter and half year ended September 30, 2026, showing 21% revenue growth and 38% increase in EBITDA for H1 FY27 compared to H1 FY26, driven by strategic expansions and acquisitions.
Anupam Rasayan India Limited
General / Other
Anupam Rasayan India Limited reported a 21% year-on-year revenue increase to Rs. 1,489 crore and a 38% rise in EBITDA to Rs. 377 crore for the half year ended September 30, 2026, reflecting strong growth in its specialty chemicals business bolstered by strategic partnerships and acquisitions.
For the quarter ended September 30, 2026, the company achieved total revenue of Rs. 821 crore, up 11% from Rs. 739 crore in the same quarter last year. EBITDA for Q2 FY27 rose 41% to Rs. 202 crore, with EBITDA margin improving to 25%. Profit after tax for the quarter stood at Rs. 65 crore compared to Rs. 57 crore in Q2 FY26.
During H1 FY27, Anupam Rasayan signed a six-year long-term supply agreement with a US-based specialty metal manufacturer to enter the geological resources sector, expanding its customer base and product applications.
Additionally, the company completed acquisition of a 50.07% controlling stake in Bliss GVS Pharma, enhancing its pharmaceutical capabilities and presence across the pharmaceutical value chain.
Anupam operates 14 manufacturing facilities across India and the US, serving over 200 domestic and international customers with specialty chemicals in life sciences and performance materials segments.
Highlights
- H1 FY27 total revenue: Rs. 1,489 crore, 21% increase YoY.
- H1 FY27 EBITDA: Rs. 377 crore, 38% increase YoY; margin at 25%.
- Q2 FY27 revenue: Rs. 821 crore, up 11% YoY.
- Q2 FY27 EBITDA: Rs. 202 crore, up 41% YoY; margin of 25%.
- Signed six-year supply deal with US specialty metals company.
- Acquired 50.07% stake in Bliss GVS Pharma for pharmaceutical sector expansion.
Key Data Snapshot
What happened
- Anupam Rasayan India Limited announced its unaudited consolidated financial results for Q2 and H1 FY27 ending September 30, 2026.
- The company reported 21% revenue growth and 38% EBITDA increase for the half year compared to H1 FY26.
- Q2 FY27 revenue rose 11% year-on-year, with EBITDA up 41%.
- Profit after tax increased 10% for H1 FY27 and 14% for Q2 FY27 compared to prior year periods.
Key details
- Signed a six-year supply agreement with a US-based specialty metal manufacturer during the quarter.
- Completed acquisition of a 50.07% controlling stake in Bliss GVS Pharma, expanding pharmaceutical segment presence.
- Operations include 14 manufacturing facilities located in Gujarat, Maharashtra, Tamil Nadu, and the US.
- Installed capacities include over 2,00,000 MT for specialty chemicals and 4,800+ million units for pharmaceutical formulations as of September 30, 2026.
Transaction details
- Acquisition of controlling interest in Bliss GVS Pharma marks strategic diversification into finished dosage formulations and pharmaceuticals.
- The six-year supply agreement represents entry into geological resources sector, diversifying customer base.
- The acquisitions and agreements are part of strengthening the company’s specialty chemicals platform globally.
Strategic context
- Company focuses on building an integrated specialty chemicals platform with expansions in pharmaceuticals, performance materials, and new applications.
- Management emphasizes disciplined execution and capital utilization to enhance manufacturing and technological capabilities.
- Expansion efforts aim to create long-term value and sustainable growth for stakeholders.
Highlights
- H1 FY27 total revenue: Rs. 1,489 crore, 21% increase YoY.
- H1 FY27 EBITDA: Rs. 377 crore, 38% increase YoY; margin at 25%.
- Q2 FY27 revenue: Rs. 821 crore, up 11% YoY.
- Q2 FY27 EBITDA: Rs. 202 crore, up 41% YoY; margin of 25%.
- Signed six-year supply deal with US specialty metals company.
- Acquired 50.07% stake in Bliss GVS Pharma for pharmaceutical sector expansion.
Disclosures
- Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Manali Petrochemicals Posts Rs. 414.37 Crore Consolidated Income for Q2 Ending September 2026 with Stable Profits
Manali Petrochemicals Limited announced its unaudited consolidated financial results for the quarter ended 30th September 2026, reporting a total income of Rs. 414.37 crore and profit before tax of Rs. 85.30 crore, with steady standalone financial performance and increased business activity.
Read Full Story
Gala Precision Engineering Limited Confirms Proper Utilization of Rs 1,353.40 Million IPO Proceeds in Q2 2026
Gala Precision Engineering Limited's Monitoring Agency report for the quarter ended September 30, 2026, states full compliance in the utilization of Rs 1,353.40 million raised through its Initial Public Offer. The funds have been deployed as disclosed in the offer document, covering a new manufacturing facility in Tamil Nadu, capital expenditure in Maharashtra, repayment of borrowings, and general corporate purposes.
Read Full Story
NGL Fine-Chem Invests in 3.10 MW Solar and 3.60 MW Wind Projects for Long-Term Renewable Energy Supply
NGL Fine-Chem Limited's Board approved entering into power purchase agreements for renewable energy from a 3.10 MW solar and a 3.60 MW wind power project in Maharashtra, alongside subscribing to 26% and 22.28% equity stakes respectively in their special purpose vehicles.
Read Full Story
